Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T therapy for refractory and relapsing ulcerative colitis
NCT07435779Phase 1Recruiting
- Sponsor
- Senlang Bio
- Start
- Feb 2026
- Primary completion
- Feb 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of BCMA-CAR-T, Autologous CD19 CAR-T (Institute of Hematology & Blood Diseases Hospital) and CD19 + BCMA CAR-T in ulcerative colitis (UC), sponsored by Senlang Bio. Primary endpoint: Incidence of Cytokine Release Syndrome and Immune Effector Cell-Associated Neurotoxicity Syndrome at 28 days. Started Feb 2026; status: recruiting.
02
Drugs
BCMA-CAR-TAutologous CD19 CAR-T (Institute of Hematology & Blood Diseases Hospital)CD19 + BCMA CAR-T
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07435779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07435779.